PLYMOUTH MEETING, Pa., April 21, 2015 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that it has initiated a phase I trial to evaluate Inovio’s DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche and Inovio entered into a partnership to co-develop and commercialize Inovio’s hepatitis B immunotherapy. This trial initiation triggers a $3 million milestone payment from Roche to Inovio.
This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio’s hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio’s IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy’s effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.Share This Page